PH12016500577B1 - Piperazine derivatives and the use thereof as medicament - Google Patents
Piperazine derivatives and the use thereof as medicamentInfo
- Publication number
- PH12016500577B1 PH12016500577B1 PH12016500577A PH12016500577A PH12016500577B1 PH 12016500577 B1 PH12016500577 B1 PH 12016500577B1 PH 12016500577 A PH12016500577 A PH 12016500577A PH 12016500577 A PH12016500577 A PH 12016500577A PH 12016500577 B1 PH12016500577 B1 PH 12016500577B1
- Authority
- PH
- Philippines
- Prior art keywords
- piperazine derivatives
- medicament
- compounds
- general formula
- glyt1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13188904 | 2013-10-16 | ||
| PCT/EP2014/072085 WO2015055698A1 (en) | 2013-10-16 | 2014-10-15 | Piperazine derivatives and the use thereof as medicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12016500577A1 PH12016500577A1 (en) | 2016-06-20 |
| PH12016500577B1 true PH12016500577B1 (en) | 2016-06-20 |
Family
ID=49354583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12016500577A PH12016500577B1 (en) | 2013-10-16 | 2016-03-30 | Piperazine derivatives and the use thereof as medicament |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9233953B2 (enExample) |
| EP (1) | EP3057963B1 (enExample) |
| JP (1) | JP6483105B2 (enExample) |
| KR (1) | KR102281284B1 (enExample) |
| CN (1) | CN105636961B (enExample) |
| AR (1) | AR098037A1 (enExample) |
| AU (1) | AU2014336258B2 (enExample) |
| BR (1) | BR112016008062B1 (enExample) |
| CA (1) | CA2926754C (enExample) |
| CL (1) | CL2016000884A1 (enExample) |
| DK (1) | DK3057963T3 (enExample) |
| EA (1) | EA029313B1 (enExample) |
| ES (1) | ES2745555T3 (enExample) |
| HU (1) | HUE047044T2 (enExample) |
| IL (1) | IL244693B (enExample) |
| MX (1) | MX370006B (enExample) |
| PH (1) | PH12016500577B1 (enExample) |
| PL (1) | PL3057963T3 (enExample) |
| TW (1) | TW201609716A (enExample) |
| UY (1) | UY35785A (enExample) |
| WO (1) | WO2015055698A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106854189A (zh) * | 2015-12-08 | 2017-06-16 | 湖南华腾制药有限公司 | 一种哌嗪化合物的合成方法 |
| CN107778257A (zh) * | 2016-08-29 | 2018-03-09 | 湖南华腾制药有限公司 | 一种哌嗪衍生物的合成方法 |
| CN106977463A (zh) * | 2017-05-31 | 2017-07-25 | 湖南华腾制药有限公司 | 一种联苯取代哌嗪衍生物的合成方法 |
| CN107417679A (zh) * | 2017-08-04 | 2017-12-01 | 河南农业大学 | 1,3‑唑类取代吡嗪类化合物的制备方法 |
| WO2021142329A1 (en) | 2020-01-09 | 2021-07-15 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
| CN117050051A (zh) * | 2023-08-14 | 2023-11-14 | 上海药坦药物研究开发有限公司 | 一种2-溴-1-（5-碘噻吩-2-基）-乙酮的纯化方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| GB0505085D0 (en) | 2005-03-11 | 2005-04-20 | Glaxo Group Ltd | Compounds |
| JP2008536950A (ja) * | 2005-04-18 | 2008-09-11 | ニューロジェン・コーポレーション | 置換ヘテロアリールのｃｂ１拮抗薬 |
| TW201105674A (en) | 2009-07-08 | 2011-02-16 | Leo Pharma As | Novel JAK receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof |
-
2014
- 2014-10-14 US US14/513,918 patent/US9233953B2/en active Active
- 2014-10-15 CA CA2926754A patent/CA2926754C/en active Active
- 2014-10-15 KR KR1020167012860A patent/KR102281284B1/ko active Active
- 2014-10-15 HU HUE14784235A patent/HUE047044T2/hu unknown
- 2014-10-15 AR ARP140103834A patent/AR098037A1/es unknown
- 2014-10-15 EA EA201600323A patent/EA029313B1/ru not_active IP Right Cessation
- 2014-10-15 TW TW103135739A patent/TW201609716A/zh unknown
- 2014-10-15 DK DK14784235.5T patent/DK3057963T3/da active
- 2014-10-15 MX MX2016004847A patent/MX370006B/es active IP Right Grant
- 2014-10-15 ES ES14784235T patent/ES2745555T3/es active Active
- 2014-10-15 PL PL14784235T patent/PL3057963T3/pl unknown
- 2014-10-15 AU AU2014336258A patent/AU2014336258B2/en active Active
- 2014-10-15 JP JP2016523968A patent/JP6483105B2/ja active Active
- 2014-10-15 BR BR112016008062-9A patent/BR112016008062B1/pt active IP Right Grant
- 2014-10-15 WO PCT/EP2014/072085 patent/WO2015055698A1/en not_active Ceased
- 2014-10-15 EP EP14784235.5A patent/EP3057963B1/en active Active
- 2014-10-15 CN CN201480056368.8A patent/CN105636961B/zh active Active
- 2014-10-16 UY UY0001035785A patent/UY35785A/es unknown
-
2016
- 2016-03-21 IL IL244693A patent/IL244693B/en active IP Right Grant
- 2016-03-30 PH PH12016500577A patent/PH12016500577B1/en unknown
- 2016-04-14 CL CL2016000884A patent/CL2016000884A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY35785A (es) | 2015-04-30 |
| ES2745555T3 (es) | 2020-03-02 |
| AU2014336258B2 (en) | 2018-07-12 |
| BR112016008062A2 (enExample) | 2017-08-01 |
| HUE047044T2 (hu) | 2020-04-28 |
| NZ718251A (en) | 2021-02-26 |
| MX370006B (es) | 2019-11-28 |
| DK3057963T3 (da) | 2019-09-16 |
| PH12016500577A1 (en) | 2016-06-20 |
| US9233953B2 (en) | 2016-01-12 |
| EA029313B1 (ru) | 2018-03-30 |
| AR098037A1 (es) | 2016-04-27 |
| CN105636961A (zh) | 2016-06-01 |
| BR112016008062B1 (pt) | 2022-11-16 |
| EP3057963B1 (en) | 2019-06-19 |
| CL2016000884A1 (es) | 2016-12-30 |
| KR20160062187A (ko) | 2016-06-01 |
| CA2926754A1 (en) | 2015-04-23 |
| TW201609716A (zh) | 2016-03-16 |
| IL244693B (en) | 2019-08-29 |
| JP6483105B2 (ja) | 2019-03-13 |
| EP3057963A1 (en) | 2016-08-24 |
| US20150105397A1 (en) | 2015-04-16 |
| JP2016533368A (ja) | 2016-10-27 |
| MX2016004847A (es) | 2016-07-19 |
| WO2015055698A1 (en) | 2015-04-23 |
| KR102281284B1 (ko) | 2021-07-23 |
| CA2926754C (en) | 2021-09-14 |
| PL3057963T3 (pl) | 2019-12-31 |
| EA201600323A1 (ru) | 2016-10-31 |
| AU2014336258A1 (en) | 2016-04-14 |
| CN105636961B (zh) | 2019-11-05 |
| IL244693A0 (en) | 2016-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501996A1 (en) | Heterocyclic compounds and uses thereof | |
| MX2015017345A (es) | Compuestos para tratar atrofia muscular espinal. | |
| EA201690598A1 (ru) | Аминогетероарил бензамиды в качестве ингибиторов киназы | |
| NZ608116A (en) | Triazine-oxadiazoles | |
| EA201690247A1 (ru) | Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения | |
| NZ716840A (en) | Combination formulation of two antiviral compounds | |
| MX2015008628A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2015017861A (es) | Derivados de benzotiofeno como inhibidores del receptor de estrogeno. | |
| NZ709211A (en) | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MD20140073A2 (en) | New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them | |
| EA201591195A1 (ru) | Новые хинолоновые производные | |
| MY197698A (en) | Oxysterols and methods of use thereof | |
| MX2014007897A (es) | Nuevos derivados de azetidina, composiciones farmaceuticas y sus usos. | |
| PH12016500577B1 (en) | Piperazine derivatives and the use thereof as medicament | |
| IN2015DN03998A (enExample) | ||
| MX362879B (es) | Usos novedosos. | |
| EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
| EA201592268A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 | |
| MX390763B (es) | Compuestos de tetraciclina | |
| IN2014DN10449A (enExample) | ||
| UA117154C2 (uk) | Антагоністи s1p3 | |
| EA201490573A1 (ru) | Соединение бензотиазолона | |
| MY181682A (en) | Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| PH12015502703A1 (en) | Pharmaceutical compositions |